Sheldon L. Koenig Esperion Therapeutics, Inc. (ESPR) insider trading activity

Sheldon L. Koenig is President and CEO of Esperion Therapeutics, Inc.. Currently has a direct ownership of 739,819 shares of ESPR, which is worth approximately $1.69 Million. The most recent transaction as insider was on Dec 17, 2024, when has been sold 12,447 shares (Common Stock) at a price of $2.47 per share, resulting in proceeds of $30,744. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 740K

1.65% 3M change

136.5% 12M change

Total Value Held $1.69 Million

Sheldon L. Koenig Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2024	SELL Open market or private sale	$30,744 $2.47 p/Share	12,447 Reduced 1.65%	739,819 Common Stock
Sep 17 2024	SELL Open market or private sale	$26,190 $1.8 p/Share	14,550 Reduced 1.9%	752,266 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	454,000 Added 37.19%	766,816 Common Stock
May 09 2023	BUY Open market or private purchase	$25,200 $1.26 p/Share	20,000 Added 6.01%	312,816 Common Stock
Mar 17 2023	SELL Open market or private sale	$12,458 $1.78 p/Share	6,999 Reduced 2.33%	292,816 Common Stock
Mar 14 2023	BUY Grant, award, or other acquisition	-	105,000 Added 25.94%	299,815 Common Stock
Mar 07 2023	SELL Open market or private sale	$27,531 $5.06 p/Share	5,441 Reduced 2.72%	194,815 Common Stock
Sep 19 2022	SELL Open market or private sale	$23,554 $6.94 p/Share	3,394 Reduced 1.68%	198,257 Common Stock
Aug 05 2022	BUY Open market or private purchase	$49,915 $5.8 p/Share	8,606 Added 4.15%	198,771 Common Stock
Jun 17 2022	SELL Open market or private sale	$22,714 $4.99 p/Share	4,552 Reduced 2.34%	190,165 Common Stock
Mar 17 2022	SELL Open market or private sale	$2,615 $4.58 p/Share	571 Reduced 0.29%	194,717 Common Stock
Mar 14 2022	BUY Grant, award, or other acquisition	-	116,000 Added 37.26%	195,288 Common Stock
Oct 29 2021	BUY Grant, award, or other acquisition	-	26,700 Added 25.82%	76,700 Common Stock
May 17 2021	BUY Grant, award, or other acquisition	-	20,000 Added 28.57%	50,000 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	30,000 Added 50.0%	30,000 Common Stock

SLK

Sheldon L. Koenig

President and CEO

Ann Arbor, MI

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Value

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR

Account